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Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant cancers. It is
characterized by a poor prognosis with a 5-year survival rate of only around 10% and an
ongoing increase in death rate. Due to the lack of early and specific symptoms, most
patients are diagnosed at an advanced or even metastasized stage, essentially limiting
curative treatment options. However, even curative resection of the primary tumor and
adjuvant therapy often fails to provide a long-term survival benefit. One reason for this
dismal situation can be seen in the evolution of therapy resistances. Furthermore, PDAC is
characterized by high intratumor heterogeneity, pointing towards an abundance of cancer
stem cells (CSCs), which are regarded as essential for tumor initiation and drug resistance.
Additionally, it was shown that the gut microbiome is altered in PDAC patients, promotes
Epithelial-Mesenchymal-Transition (EMT), determines responses towards chemotherapy,
and affects survival in PDAC patients. Given the established links between CSCs and EMT
as well as drug resistance, and the emerging role of the microbiome in PDAC, we
postulate that the composition of the microbiome of PDAC patients is a critical
determinant for the abundance and plasticity of CSC populations and thus tumor
heterogeneity in PDAC. Unravelling this complex interplay might pave the way for novel
treatment strategies.
Keywords: PDAC, microbiome, CSC, microbiome-targeted therapy, drug resistance, tumor heterogeneity,
cancer stemnessSeptember 2021 | Volume 11 | Article 7406061
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Pancreatic ductal adenocarcinoma (PDAC) is one of the most
common lethal cancer entities with hardly 10% of the patients
surviving up to 5 years after diagnosis (1). Owing to the lack of
early and specific symptoms, the majority of patients are
diagnosed at an advanced- or even metastasized stage (2). This
also implies that only 20% of the patients are eligible for resection
of the primary tumor combined with adjuvant chemotherapy.
However, in most cases even this curative treatment regimen
only provides a temporary survival benefit, due to relapse or the
development of metastases during or shortly after therapy. One
reason for this poor prognosis can be seen in the evolution of
resistances towards therapeutic drugs, e.g. through the activation
of multidrug resistance and pro-survival pathways (3–5).
Furthermore, PDAC is characterized by a pronounced
inflammatory tumor stroma, which besides genetic and
epigenetic alterations also contributes to the acquisition of a
drug resistant phenotype in PDAC cells (6, 7).
The emergence of chemoresistance has been linked to
Epithelial-Mesenchymal-Transition (EMT) in diverse cancer
entities, including PDAC (8–11). Primarily, EMT is regarded
as a key process in metastasis by which epithelial tumor cells
acquire the capability to disconnect from the primary context
and disseminate to secondary sites. Since EMT can also be seen
as a dedifferentiation process, it is not surprising that EMT has
been associated with the acquisition of cancer stem cell (CSC)
properties. Due to their self-renewal potential and ability to
undergo asymmetric cell division, CSCs are undifferentiated cells
that are essential for tumor initiation and the emergence of more
differentiated cell clones within the tumor. Thus, intratumor
heterogeneity of PDAC might be another determinant for the
response to therapeutic drugs, as particularly CSCs are highly
resistant to cancer therapies (12–16).
As outlined in the review by Zhang et al. recently published in
Frontiers in Oncology, the gut and tumor microbiome have
emerged as a promising therapeutic target for PDAC (8, 17, 18),
due to its impact on tumorigenesis and drug resistance in PDAC
(19, 20). Several studies in PDAC patients demonstrated
important links between the patient`s tumor microbiome and
disease progression, such as correlations between patient survival
and tumor microbiome diversity (21) or facilitating immune
suppression (19). These findings support a link between the
microbiome, disease progression and outcome of PDAC patients.
Moreover, chronic inflammation associated with long-term
microbial infection promotes EMT, which in turn contributes
to drug resistance, cancer progression and metastasis
(summarized in 8). Since EMT is linked to the acquisition of
CSC properties, we postulate that the abundance and plasticity of
CSCs, and thereby intratumor heterogeneity in PDAC, are
critically modulated by the patient`s microbiome (of differentAbbreviations: CDD, cytidine deaminase; CSC, cancer stem cell; CTLA-4,
cytotoxic T-lymphocyte-associated protein 4; EMT, Epithelial-Mesenchymal-
Transition; FMT, fecal microbiota transplant; IPMNs, intraductal papillary
mucinous neoplasms; LTS, long-term survivors; MET, Mesenchymal-Epithelial-
Transition; PDAC, Pancreatic ductal adenocarcinoma; STS, short-term survivors.
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might provide the basis for innovative therapeutic strategies
targeting the microbiome.EPITHELIAL-MESENCHYMAL-TRANSITION
EMT is regarded as a prerequisite for epithelial/carcinoma cells
to disseminate from the primary tumor to secondary sites.
Undergoing this process implies a loss of typical epithelial
characteristics and a gain of mesenchymal properties, causing a
fundamental functional switch from stationary to a more motile
and invasive phenotype. In detail, expression of epithelial
proteins like E-cadherin or occludin, both being important for
epithelial cell-cell contacts, are diminished, while expression of
mesenchymal markers such as N-cadherin, Vimentin, L1CAM
or the transcription factor Zeb1 are enhanced (22). Accordingly,
EMT is a process by which cells lose their original differentiation
and function, which can be regained at secondary sites by
reversion of EMT, a process called Mesenchymal-Epithelial-
Transition (MET). Thus, it is not surprising that EMT
coincides with the acquisition of CSC-characteristics in tumor
cells (23–25). Mani et al. demonstrated that breast cancer cells
that have undergone EMT acquire a stem cell-like phenotype,
and subsequently these stem cell-like cells resemble cells that
have undergone EMT (25).CANCER STEM CELLS
Similar to physiological stem cells, CSCs are characterized by the
ability to proliferate indefinitely and to divide asymmetrically,
giving rise to both stem cells and differentiated short-lived
daughter cells with limited proliferative capability (26–29).
Based on these properties, CSCs - although accounting only
for a small part of the entire tumor cell population - are regarded
as essential for tumor initiation and progression as well as for
tumor heterogeneity (27, 30–32). According to the current
model, CSCs are not a fixed cell population, but that the
aforementioned characteristics can be acquired and lost
dependent on environmental stimuli, as CSC are highly
dependent on their niche, i.e. oxygen level, surrounding
stromal cells and their released factors (24, 29, 33–36). Hence,
factors like oxidative, inflammatory and nutritional stress, to
which tumor cells are commonly subjected to, determine the
differentiation of non-CSCs into CSCs and vice versa. From an
evolutionary point of view, this model implies that changes in the
tissue microenvironment (e.g., inflammation and/or microbiome
changes) lead to the selection of subpopulations of CSCs in a
Darwinian manner. As a consequence, these CSCs develop
strategies that enable them to survive the adverse conditions of
the host (37). This might also provide an explanation for the
marked resistance of CSCs to different therapies (8). For
instance, chemotherapies aim to decrease the total number of
rapidly proliferating tumor cells. However, since CSCs rarely
divide and exhibit high levels of drug export molecules, this isSeptember 2021 | Volume 11 | Article 740606
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be removed while CSCs survive and can give rise to recurrences
or metastases (30, 38–42).
In summary, CSCs contribute to tumorigenicity, tumor
progression, metastasis, recurrence as well as therapy resistance
in PDAC (26, 42, 43). Given the fact that EMT as well as the
interconversion from non-CSC to CSC are both processes
defining tumor cell plasticity and heterogeneity, and either
process is highly dependent on the inflammatory/stress level of
the surrounding microenvironment, it is reasonable to postulate
that the microbiome is another important determinant for
defining evolution of CSC. Confirming the contribution of the
microbiome to tumor cell plasticity might provide additional
mechanistic insight into tumorigenesis and the survival of
PDAC patients.THE MICROBIOME - PDAC AXIS
Alterations of the Microbiome in
PDAC Patients
The human gut microbiota is comprised of a collection of
different bacteria, archaea, fungi, viruses and protozoa. Its
composition is unique to each individual and is influenced by
a variety of environmental factors such as the mode of birth, age,
diet, and, disease (44, 45). The microbiome plays vital roles in
immune development, nutrition, energy metabolism and host
defense (45). Generally, a higher bacterial diversity is
characteristic of a healthy gut microbiome, whereas low
diversity accompanies diseases such as inflammatory bowel
disease, diabetes mellitus type 2, asthma and various cancers
(46–50). An inflammatory environment favors pro-
inflammatory bacteria in the diseased gut, thereby establishing
a cycle of inflammation (51). In some cases of Enterococcus
faecalis infection, the bacterium infiltrates the patient´s pancreas
and initiates inflammation, resulting in the progression of
chronic pancreatitis (52). A state of chronic inflammation as
manifested e.g. in chronic pancreatitis or Helicobacter pylori
infection in the gut is a known risk factor of PDAC
development (53–55). Several routes by which bacteria can
migrate into the PDAC microenvironment have been
proposed, such as through the bile duct, portal circulation
system or mesenteric lymph nodes (8). A number of studies
support these routes, for example microbiome analysis of the cyst
fluid of intraductal papillary mucinous neoplasms (IPMNs) with
high-grade dysplasia revealed the presence of Fusobacterium
nucleatum and Granulicatella adiacens, which are commonly
found in the oral cavity (56, 57). In line with these findings,
Mitsuhashi et al. identified Fusobacterium species being
enhanced in tumor tissues of PDAC patients and associated
with a worse prognosis (58).
The study by Geller et al. revealed that most bacterial species
that were identified by 16S rRNA gene sequencing in PDAC
tissues belong to Gammaproteobacteria and are predominantly
members of the Enterobacteriaceae and Pseudomonadacea
families (17). Furthermore, pancreas, bile, and jejunumFrontiers in Oncology | www.frontiersin.org 3samples from patients undergoing pancreaticoduodenectomy
showed a distinctly different microbiome than healthy controls
(59). Although the process of bacterial translocation from the
oral cavity and gut into the pancreatic (tumor) tissue is not fully
understood, we can speculate on the factors and mechanisms
that favor this migration. For example, the formation of a new
niche that offers lower colonization resistance and provides
nutrition in the form of increased glycan levels might favor the
migration of bacteria into the tumor microenvironment (60). In
line with this hypothesis, the tumor microenvironment is
enriched with structural proteins, proteoglycans, adapter
proteins and enzymes, as well as tumor associated
inflammatory cells such as myofibroblasts or macrophages,
which are known producers of the aforementioned factors
(61). Together, these changes in the microenvironment provide
advantageous conditions that may facilitate bacterial migration
from the gut into the pancreas on the one hand, and promote
tumor development and progression on the other hand.
Impact of an Altered Microbiome on EMT
and Therapy Resistance
I t was demonstrated that an inflammatory tumor
microenvironment and tumor associated microbiome can
promote EMT by inducing various signaling pathways that
lead to the activation of different EMT transcription factors.
Thus, it could be shown that infections by certain pathogens such
as F. nucleatum are able to induce phosphorylation, and thus
internalization of the epithelial marker protein E-cadherin. This
in turn mediates the release of bound b-catenin, which
translocates into the nucleus and influences the expression of
EMT related genes. As a consequence, tumor cells undergo EMT
and become capable of leaving the primary tumor and
disseminate to secondary sites (8, 54, 55, 62). Given the fact
that Fusobacteria species are already enriched in premalignant
lesions such as IPMN, and their abundance in PDAC tissues is
associated with a worse outcome (56, 58), it seems plausible that
their abundance contributes to PDAC progression by EMT
induction. Importantly, a distinct tumor microbiome was
shown to clearly discriminate long-term survivor (LTS) from
short-term survivor (STS) PDAC patients. Performing
taxonomic profiling of bacterial DNA from 36 LTS and 32 STS
PDAC patients revealed a higher species diversity in tumor
samples of LTS patients associated with a significantly longer
overall survival (median survival: 9.66 years) compared to STS
patients with a low diversity (median survival: 1.66 years) (21).
Overall, these findings strongly support a tumor promoting role
of the microbiome and its suitability as a potential therapeutic
target. This view is further supported by recent studies indicating
that microbes residing in the tumor microenvironment can
contribute to drug resistance, which is a major problem in
PDAC treatment. In detail, Geller et al. (17) identified that the
tumor microbiome of PDAC patients shows a high abundance of
bacterial species belonging to the class Gammaproteobacteria.
These bacteria express the enzyme cytidine deaminase (CDD)
predominantly in its long form, which enables the
metabolization of the chemotherapeutic drug gemcitabineSeptember 2021 | Volume 11 | Article 740606
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treatment of PDAC patients in the adjuvant and palliative
setting, into its inactive form (2′,2′-difluorodeoxyuridine) (17).
Besides demonstrating a novel tumor promoting role of
microbiota, these findings suggest a potential mutualistic
relationship between tumor cells and bacteria, with both of
them exhibiting a form of parasitism towards the host.
Furthermore, it can be postulated that the presence of a
distinct microbiome provides favorable conditions for selection
and survival of those tumor cell clones that have evolved the best
survival strategies and exhibit a high degree of plasticity, such as
CSCs. Enrichment and survival of CSCs within the tumor
essentially add to PDAC development and progression on the
one hand, and therapy resistance on the other hand.
First Approaches Towards Microbiome
Targeted Therapy
Therapy resistance, e.g. against cytostatic drugs, but also
immunotherapies such as cytotoxic T-lymphocyte-associated
protein 4 (CTLA-4) inhibitors, is still a major clinical challenge
in the treatment of PDAC patients, and has been related to tumor
heterogeneity implying the presence of CSCs (12–16). As
outlined above, evidence supporting a tumor-promoting role of
an altered host microbiome at different sites is accumulating.
Pathological microbiome alterations apparently contribute to
tumor development and progression in different ways, e.g. by
shaping host immunity, impacting differentiation processes such
as EMT and determining the efficacy of PDAC therapy (17–19).
Preclinical studies already strongly support the concept of
modulating the host`s microbiome to improve treatment
responses in PDAC, whereby antibiotic-treated mice displayed
a marked anti-tumor response to gemcitabine compared to the
control mice, which exhibited rapid tumor progression.
Additionally, histological analysis of tumor tissues revealed
more apoptosis induction in tumor cells when gemcitabine was
applied in combination with antibiotics compared to
gemcitabine monotherapy (17).
Furthermore, fecal microbiota transplant (FMT) has gained
attention as a promising anti-tumor therapy (21). Thus, an
increase in tumor growth was observed in mice after FMT from
STS PDAC patients compared to that from LTS PDAC patients
(21). These findings correlated with the microbiome composition
and overall survival times of these patients, and indicate that the
transplanted microbiome from STS patients promotes tumor
growth, while that from LTS PDAC patients displays the
opposite effect, leading to a slower tumor growth compared to
the control group without FMT (21). Furthermore, this study
revealed a strong correlation between microbiome diversity and
elevated numbers of CD3+, CD8+ and Granzyme B+ T cells in
tumor tissues of LTS PDAC patients compared to STS patients.
These results support the view that the tumor microbiome
modulates immunity in the tumor microenvironment, and thus
influences the dynamic interplay between tumor and immune
cells during tumorigenesis. In this context, a preclinical study
showed that the efficacy of the CTLA-4 inhibitor Ipilimumab is
increased in the presence of the gut commensal Bacteroides spp.,Frontiers in Oncology | www.frontiersin.org 4which could in turn be reverted upon administration of
antibiotics (18). The presence of these commensals affects
interleukin-12 dependent T helper-1 immune responses, which
in turn modulates tumor control in mice and humans while
preserving intestinal integrity. These findings thus point toward a
role of gut commensals in shaping the host immune response and
thereby controlling tumor growth. Overall, these findings indicate
that the composition of the tumor- as well as the gut microbiome
are essential determinants of PDAC evolution and therapeutic
responses (17, 18, 20). Table 1 lists recent studies that have found
tangible associations between disease progression and immune
regulation with the host microbiome composition. As already
mentioned above some of these studies have even singled out
distinct groups of bacteria that influenced these changes.
Naturally, clinical trials focusing on compiling 16S rRNA
profiles of PDAC patient samples are on the rise (based on
http://clinicaltrials.gov/). There is mounting evidence that
patient microbiome composition can be used as a biomarker
for disease progression as well as to increase therapeutic efficacy
of PDAC treatment (Table 1). Likewise, Leinwand & Miller
propose selectively tailoring PDAC therapy with respect to the
patients’ intratumoral and gut microbiome to enhance
therapeutic efficacy (66).
Based on these results it can be envisioned that the above-
mentionedmicrobiomemodulating strategies increase therapeutic
responses and survival of PDAC patients by lowering the
abundance of CSC (properties). Fortunately, there are already
ongoing randomized clinical trials that combine 16S rRNA gene
analysis, FMT or probiotics along with chemotherapeutics and are
listed in the review by Ciernikova et al. (57). The upcoming results
may thus further substantiate the interrelationship of the host`s
microbiome and tumor cells and provide the basis of novel
therapeutic concepts of PDAC therapy.DISCUSSION AND FUTURE PERSPECTIVES
As summarized above and in the recently published review by
Zhang et al. in this journal (8), the microbiome composition (in
different body compartments) is considerably altered in PDAC
patients compared to healthy individuals. This altered diversity
may be a consequence of tumorigenesis, as the evolution of an
inflammatory tumor microenvironment might promote bacterial
translocation from the gut into the pancreas (8, 17, 21, 57).
Besides, there is growing evidence that the microbiome is an
important determinant of PDAC development and therapy
response (8, 17, 21, 67–69). One mechanism by which the
microbiome composition seems to drive PDAC progression
and therapy resistance is promoting EMT. Importantly, EMT
induction has been linked to the acquisition of CSC properties,
and both EMT cells and CSC are characterized by profound drug
resistance (30, 38–40). Considering these well-established
interrelationships, it is reasonable to speculate that the
abundance and plasticity of CSCs, and thereby intratumor
heterogeneity in PDAC and patient´s outcome, are essentially
influenced by the patient`s microbiome (Figure 1). ThisSeptember 2021 | Volume 11 | Article 740606
TABLE 1 | Compilation of studies on the impact of the microbiome in cancer progression and drug resistance as well as its potential as a biomarker or therapeutic target.
Biomarker/Target Potential Reference
Ipilimumab in presence of Bacteroides spp. Increases
response to CTLA4 blockade. Detection of Bacteroides
spp. as predictive biomarker CTLA4 inhibition therapy
(18)
(PD-L1)–specific antibody therapy in combination with oral
Bifidobacterium administration exerts anti-tumor effect.




Gemcitabine in combination with ciprofloxacin increases the
antitumor response;
Detection of CDD and bacteria as a predictive biomarker for
gemcitabine treatment
(17)




Detection of Pseudoxanthomonas, Saccharopolyspora and
Streptomyces as a prognostic biomarker
(21)











Detection of Enterobacter and Enterococcus spp may serve




Ensuring the presence of an intact gut microbiome prior to
therapy may boost treatment efficacy
(20)
robiome
Possible supplementation of probiotic cocktails containing
beneficial bacteria may increase anti–PD-1 antibody efficacy
(64)










































Study system Targeted Pathway/
Treatment
Specific Microbiome
MCA205 sarcomas in mice housed in specific
pathogen–free (SPF) versus germ-free (GF)
conditions
CTLA-4 Bacteroides thetaiotaomicron or Bacteroides fragilis
Subcutaneous B16.SIY melanoma in C57BL/6
mice with different microbiomes
Programmed cell death
protein 1 ligand 1
(PD-L1)
Bifidobacterium




Bacteria expressing long isoform of bacterial enzyme cy
deaminase (CDD) e.g.: Gammaproteobacteria, & M. hyo
which expresses the (short isoform) renders gemcitabine
ineffective.
Formalin-fixed, paraffin-embedded (FFPE) patient
tissue specimens of PDAC patients
NA Fusobacterium species positively correlated with worse pro
Bacterial DNA from surgically resected (LTS &
STS) patient PDAC tumors
NA LTS patients were enriched in Proteobacteria
(Pseudoxanthomonas) and Actinobacteria (Saccharopol
and Streptomyces)
Orthotopically implanted KPC PDAC cell lines in
antibiotic- treated C57BL/6 mice
NA FMT from LTS patient stool samples inhibited tumor gro
Cyst fluid and peripheral blood liquid biopsies
from patients with suspected pancreatic
cystic lesions
NA Intracystic bacterial DNA quantity positively correlated w
neoplastic grade severity of IPMN, like G. adiacens, F.
nucleatum, P. micra, E. corrodens, H. parahaemolyticus
odontolyticus, P. melaninogenica and Campylobacter sp
Pancreatic juice and bile from PDAC and CP
patients; caerulein-injected mice model for CP
NA Enterobacter and Enterococcus spp were detected in
pancreatic tissue and bile from PDAC and CP patients a
CP mice but not in controls suggesting these bacteria m
involved in CP and PDAC development
Antibiotic treated C57Bl/6 mice inoculated with




Antibiotic treated mice showed impaired therapy efficac
resulted in lower cytokine production and tumor necros
CpG-oligonucleotide based immunotherapy.
Germ-free mice transplanted with responder fecal
material and later inoculated with B16.SIY
melanoma cells
Programmed cell death
protein 1 ligand 1
(PD-L1)
Bifidobacterium longum, Collinsella aerofaciens, and
Enterococcus faecium were abundantly found in the mic
of the responders to anti-PD-1-based immunotherapy
KRASG12D TP53R172HPdx-Cre (KPC) mice NA Distinct microbial dysbiosis was observed with PDAC tumo
KRASG12D TP53R172HPdx-Cre (KPC) mice and
fecal samples of PDAC patients
Innate and adaptive
immune cell signaling
Proteobacteria, Actinobacteria, Fusobacteria, and
Verrucomicrobia was enriched in the pancreatic microbi
PDAC patients and repopulation of antibiotic ablated mi











Basu et al. Microbiome Impacts Cancer Stemnesshypothesis is in line with studies supporting the fact that CSC
properties can be gained or lost depending on the tumor
microenvironment (24, 33–36). Since it is well known that an
inflammatory microenvironment impacts the phenotype and
genotype of tumor cells, it can be assumed that the altered
composition of the gut as well as the tumor microbiome
contribute to the inflammatory processes and thereby to the
switch from a physiological (tumor suppressive) into an
inflammatory (tumor promoting) tumor microenvironment.
This in turn may induce EMT and CSC-properties in PDAC
cells, e.g. by elevated levels of EMT/CSC inducing factors such as
Transforming Growth Factor-beta1 or Tumor Necrosis Factor-
alpha. Further, it cannot be ruled out that bacteria and their
released factors directly induce EMT, as it could be demonstratedFrontiers in Oncology | www.frontiersin.org 6for F. nucleatum, and also promote the gain of CSC properties
(56, 57, 61). A high abundance of CSCs in PDAC tissues could be
related to PDAC dissemination, and with this progression and
resistance to therapy (26, 31, 39, 41, 70–72). Hermann et al. (73)
demonstrated that different CSC populations exist in PDAC and
exhibit distinct functional capabilities. Thus, CD133+CXCR4+
CSCs were found to be particularly responsible for metastasis
(73). Adding to the view of CSC heterogeneity in PDAC, own
unpublished data indicate that PDAC cells can exhibit different
CSC phenotypes that are characterized by distinct CSC marker
expression (high Sox2 or high Nestin expressing CSCs) along
with different migratory and invasive abilities. As a consequence,
different metastasis patterns can be observed in a preclinical
PDAC metastasis model (unpublished data). In line with this,A
B
C
FIGURE 1 | The microbiome impacts clonal heterogeneity of PDAC cells and thereby a patient´s outcome. Changes in the microbiome composition (in the tumor but
also other body compartments) may influence Epithelial-Mesenchymal-Transition (EMT) and the abundance and phenotype of cancer stem cells (CSCs) in the tumor
by generating optimal niche conditions and impacting their survival and expansion. This in turn impacts PDAC growth and progression as well as therapy responses
and outcome of PDAC patients. (A) Microbiome diversity A (MD A) may prevent/control EMT induction and the enrichment of CSCs (CSC ↓), thereby inhibiting PDAC
progression, drug resistance and (C) improving patient´s prognosis. (B) In contrast, microbiome diversity B (MD B) may induce EMT and increase the CSC potential
within a tumor (CSC↑). As a consequence, a high CSC abundance promotes PDAC progression and drug resistance leading to (C) poor patient´s outcome.
The figure was created with BioRender.com.September 2021 | Volume 11 | Article 740606
Basu et al. Microbiome Impacts Cancer StemnessNestin was found to be upregulated in various human
malignancies (74, 75) including PDAC, where it associated
with an elevated liver metastatic potential of CSCs (31, 75).
Considering this profound knowledge, we postulate that a more
diverse microbiome composition, which was detected in LTS
PDAC patients (21), might act in favor of a host defense by
controlling the number and phenotype of CSCs in PDAC,
resulting in a lower metastatic potential and less resistance
towards chemotherapy (Figure 1A).
Accordingly, future studies are urgently needed to explore
whether- and how a certain microbiome composition (e.g., those
of LTS patients or Fusobacteria) influences intratumor
heterogeneity through the gain and loss of CSC phenotypes,
and in turn determines disease progression, therapy responses
and survival of PDAC patients. Furthermore, since it is known
that certain bacteria can increase the efficacy of therapy (18), the
potential of microbiome modulation as an integral part of anti-
cancer therapy needs to be further investigated. Given the fact
that CSCs are mandatory for tumor initiation, novel therapeutic
concepts aimed at their complete eradication. However, since the
CSC pool can be constantly regenerated by conversion of non-
CSC into CSCs, these strategies will likely ultimately fail. Instead,
therapeutic strategies aiming to prevent or control CSCs may be
more effective. Thus, the therapeutic enrichment of certain
bacteria and/or restoring (physiological) microbiome diversity
might be a promising strategy to effectively suppress theFrontiers in Oncology | www.frontiersin.org 7appearance, heterogeneity and survival of CSCs, thereby
controlling disease progression and increasing the efficacy
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